We develop optical biosensing solutions for label-free biomolecular binding studies. We have a spectrometer being sold on the market as a base product. Based on a patent-pending new Plasmon resonance sensing technology, we are developing a system that can measure binding kinetics with very small sample volume and better sensitivity than other available solutions on the market. We are also exploring novel thin film sensor solutions for the problem. Our approach enables measurement of background refractive index simultaneously and independently from binding signal, therefore gives a reliable binding measurement. The sensor system is very compact, uses microoptical components, and scaling to 96-well plates is straightforward. Such a system can find great application in drug development. Electronics scaling is also facilitated by integrated ADCs on each sensor. Based on this technology, we are also developing a compact diagnostic system for point-of-care and home use, that will operate as ...
We develop optical biosensing solutions for label-free biomolecular binding studies. We have a spectrometer being sold on the market as a base product. Based on a patent-pending new Plasmon resonance sensing technology, we are developing a system that can measure binding kinetics with very small sample volume and better sensitivity than other available solutions on the market. We are also exploring novel thin film sensor solutions for the problem. Our approach enables measurement of background refractive index simultaneously and independently from binding signal, therefore gives a reliable binding measurement. The sensor system is very compact, uses microoptical components, and scaling to 96-well plates is straightforward. Such a system can find great application in drug development. Electronics scaling is also facilitated by integrated ADCs on each sensor. Based on this technology, we are also developing a compact diagnostic system for point-of-care and home use, that will operate as a multichannel lateral flow assay, however based on SPR and therefore highly sensitive and quantitative. Such a platform will enable monitoring health markers for CVD or various types of chronic and infectious diseases.
More information

Employees

Aykutlu Dana
Admin
Aykutlu Dana CTO I am a Stanford PhD, Electrical Engineer, with 15+ years experience in optical biosensing and 20+ years experience in optics